These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 1898640

  • 1. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group.
    Henthorn RW, Waldo AL, Anderson JL, Gilbert EM, Alpert BL, Bhandari AK, Hawkinson RW, Pritchett EL.
    Circulation; 1991 Jan; 83(1):119-25. PubMed ID: 1898640
    [Abstract] [Full Text] [Related]

  • 2. Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group.
    Bhandari AK, Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Cullen MT, Hawkinson RW, Pritchett EL.
    Am Heart J; 1992 Aug; 124(2):381-6. PubMed ID: 1636582
    [Abstract] [Full Text] [Related]

  • 3. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.
    Circulation; 1995 Nov 01; 92(9):2550-7. PubMed ID: 7586356
    [Abstract] [Full Text] [Related]

  • 4. A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. The Flecainide Multicenter Investigators Group.
    Dorian P, Naccarelli GV, Coumel P, Hohnloser SH, Maser MJ.
    Am J Cardiol; 1996 Jan 25; 77(3):89A-95A. PubMed ID: 8607397
    [Abstract] [Full Text] [Related]

  • 5. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
    Hopson JR, Buxton AE, Rinkenberger RL, Nademanee K, Heilman JM, Kienzle MG.
    Am J Cardiol; 1996 Jan 25; 77(3):72A-82A. PubMed ID: 8607395
    [Abstract] [Full Text] [Related]

  • 6. Flecainide single oral dose for management of paroxysmal supraventricular tachycardia in children and young adults.
    Musto B, Cavallaro C, Musto A, D'Onofrio A, Belli A, De Vincentis L.
    Am Heart J; 1992 Jul 25; 124(1):110-5. PubMed ID: 1615792
    [Abstract] [Full Text] [Related]

  • 7. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.
    Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett EL.
    Circulation; 1989 Dec 25; 80(6):1557-70. PubMed ID: 2513143
    [Abstract] [Full Text] [Related]

  • 8. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group.
    Pritchett EL, DaTorre SD, Platt ML, McCarville SE, Hougham AJ.
    J Am Coll Cardiol; 1991 Feb 25; 17(2):297-303. PubMed ID: 1899432
    [Abstract] [Full Text] [Related]

  • 9. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group.
    Anderson JL, Platt ML, Guarnieri T, Fox TL, Maser MJ, Pritchett EL.
    Am J Cardiol; 1994 Sep 15; 74(6):578-84. PubMed ID: 8074041
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo.
    Tendera M, Wnuk-Wojnar AM, Kulakowski P, Malolepszy J, Kozlowski JW, Krzeminska-Pakula M, Szechinski J, Droszcz W, Kawecka-Jaszcz K, Swiatecka G, Ruzyllo W, Graff O.
    Am Heart J; 2001 Jul 15; 142(1):93-8. PubMed ID: 11431663
    [Abstract] [Full Text] [Related]

  • 11. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias.
    Wanless RS, Anderson K, Joy M, Joseph SP.
    Am Heart J; 1997 Apr 15; 133(4):441-6. PubMed ID: 9124166
    [Abstract] [Full Text] [Related]

  • 12. Electrophysiologic effects and therapeutic efficacy of intravenous flecainide for termination of paroxysmal supraventricular tachycardia.
    Gambhir DS, Bhargava M, Arora R, Khalilullah M.
    Indian Heart J; 1995 Apr 15; 47(3):237-43. PubMed ID: 7558090
    [Abstract] [Full Text] [Related]

  • 13. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
    Chimienti M, Cullen MT, Casadei G.
    Eur Heart J; 1995 Dec 15; 16(12):1943-51. PubMed ID: 8682031
    [Abstract] [Full Text] [Related]

  • 14. [Electrophysiological effects and clinical efficacy of flecainide in childhood patients with supraventricular reciprocating paroxysmal tachycardia].
    Musto B, D'Onofrio A, Cavallaro C, Musto A, Della Gatta O, Marsico F.
    G Ital Cardiol; 1987 May 15; 17(5):444-9. PubMed ID: 3115857
    [Abstract] [Full Text] [Related]

  • 15. Opposite effects of propafenone and flecainide in a patient with reciprocating supraventricular tachycardia.
    Montenero AS, Natale A, di Bona G, Calvi V, Santarelli P, Manzoli U.
    Cardiologia; 1990 Mar 15; 35(3):253-6. PubMed ID: 2123130
    [Abstract] [Full Text] [Related]

  • 16. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response.
    Page RL, Connolly SJ, Wilkinson WE, Marcello SR, Schnell DJ, Pritchett EL, Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators.
    Am Heart J; 2002 Apr 15; 143(4):643-9. PubMed ID: 11923801
    [Abstract] [Full Text] [Related]

  • 17. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group.
    DiMarco JP, Miles W, Akhtar M, Milstein S, Sharma AD, Platia E, McGovern B, Scheinman MM, Govier WC.
    Ann Intern Med; 1990 Jul 15; 113(2):104-10. PubMed ID: 2193560
    [Abstract] [Full Text] [Related]

  • 18. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial.
    Stambler BS, Camm AJ, Alings M, Dorian P, Heidbuchel H, Houtgraaf J, Kowey PR, Merino JL, Mondésert B, Piccini JP, Pokorney SD, Sager PT, Verma A, Wharton JM, Bharucha DB, Plat F, Shardonofsky S, Chen M, Ip JE, RAPID Investigators.
    Lancet; 2023 Jul 08; 402(10396):118-128. PubMed ID: 37331368
    [Abstract] [Full Text] [Related]

  • 19. First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301).
    Stambler BS, Plat F, Sager PT, Shardonofsky S, Wight D, Potvin D, Pandey AS, Ip JE, Coutu B, Mondésert B, Sterns LD, Bennett M, Anderson JL, Damle R, Haberman R, Camm AJ.
    Circ Arrhythm Electrophysiol; 2022 Dec 08; 15(12):e010915. PubMed ID: 36441560
    [Abstract] [Full Text] [Related]

  • 20. Flecainide acetate for long-term prevention of paroxysmal supraventricular tachyarrhythmias.
    Benditt DG, Dunnigan A, Buetikofer J, Milstein S.
    Circulation; 1991 Jan 08; 83(1):345-9. PubMed ID: 1898643
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.